Sign in with your email address username.


[Comment] Large-scale screening for somatic mutations in lung cancer

Lung cancer is the leading cause of cancer-related death worldwide. More than 85% of cases are classified as non-small-cell lung cancer (NSCLC), with predicted 5-year survival of 16%. However, technological advances in the past decade, including the introduction of next-generation sequencing, have allowed for identification of several genetic mutations.1 These mutations are considered to be actionable oncogenic drivers (ie, treatable with specific drugs) since they cause specific subclasses of NSCLC, and therefore can be targeted with selective inhibitors.